Capital Advisors Inc. OK Buys 73,379 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Capital Advisors Inc. OK increased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 34.7% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 284,738 shares of the company's stock after acquiring an additional 73,379 shares during the period. Capital Advisors Inc. OK owned about 0.32% of Intellia Therapeutics worth $8,682,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. ARK Investment Management LLC lifted its stake in Intellia Therapeutics by 14.7% in the fourth quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company's stock worth $347,966,000 after purchasing an additional 1,463,820 shares during the last quarter. Morgan Stanley raised its stake in shares of Intellia Therapeutics by 64.5% during the fourth quarter. Morgan Stanley now owns 2,518,150 shares of the company's stock valued at $87,858,000 after acquiring an additional 987,599 shares during the last quarter. Norges Bank bought a new position in shares of Intellia Therapeutics during the fourth quarter valued at about $29,910,000. Rhenman & Partners Asset Management AB raised its stake in shares of Intellia Therapeutics by 1,600.0% during the third quarter. Rhenman & Partners Asset Management AB now owns 850,000 shares of the company's stock valued at $26,877,000 after acquiring an additional 800,000 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Intellia Therapeutics by 31.1% during the second quarter. State Street Corp now owns 3,143,811 shares of the company's stock valued at $162,724,000 after acquiring an additional 746,284 shares during the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP James Basta sold 2,297 shares of the stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $32.99, for a total transaction of $75,778.03. Following the sale, the executive vice president now owns 81,571 shares in the company, valued at $2,691,027.29. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 3.00% of the company's stock.

Intellia Therapeutics Trading Down 3.0 %

NTLA traded down $0.74 during midday trading on Friday, reaching $24.27. The company's stock had a trading volume of 1,295,745 shares, compared to its average volume of 1,143,724. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of -4.49 and a beta of 1.77. Intellia Therapeutics, Inc. has a 1 year low of $22.67 and a 1 year high of $47.48. The stock's 50-day moving average is $27.69 and its 200-day moving average is $28.20.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) earnings per share for the quarter, topping analysts' consensus estimates of ($1.47) by $0.01. The business had revenue of ($1.92) million for the quarter, compared to analysts' expectations of $15.10 million. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. During the same quarter in the prior year, the company earned ($1.40) earnings per share. As a group, equities research analysts forecast that Intellia Therapeutics, Inc. will post -5.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NTLA has been the subject of several recent analyst reports. The Goldman Sachs Group downgraded shares of Intellia Therapeutics from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $136.00 to $32.00 in a research note on Friday, February 23rd. Canaccord Genuity Group upped their price objective on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the company a "buy" rating in a research note on Friday, February 23rd. Wolfe Research began coverage on shares of Intellia Therapeutics in a research note on Thursday, February 15th. They issued a "peer perform" rating for the company. Finally, Wedbush reissued a "neutral" rating and issued a $29.00 price target on shares of Intellia Therapeutics in a research note on Thursday, February 15th. One analyst has rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $67.00.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.